@article{fdi:010081632,
  title = {{HIV} contamination of commercial {PCR} enzymes raises the importance of quality control of low-cost in-house genotypic {HIV} drug resistance tests},
  author = {{M}onleau, {M}. and {P}lantier, {J}. {C}. and {P}eeters, {M}artine},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {L}ow-cost in-house technologies for genotypic drug resistance testing use reagents with quality labels for research only. {H}ere, we report on the results of {PCR} amplifications in negative-controls that were observed in two independent laboratories. {M}ethods: {P}ositive {PCR} amplifications of protease and reverse transcriptase fragments for genotypic drug resistance testing of {HIV} on dried blood and/or plasma spots were observed on negative-control samples and were analysed in detail by {PCR} and sequence and phylogenetic analyses to identify the origin of the {PCR} contamination. {R}esults: {D}etailed analysis revealed that the {RT}-{PCR} enzymes were contaminated with an {HIV}-based vector commercialized by the same company. {C}onclusions: {T}hese observations show the need to implement quality control steps that verify for the absence of {HIV} in new reagent batches because this can significantly compromise molecular diagnosis of {HIV} and genotypic drug resistance tests using in-house protocols.},
  keywords = {},
  booktitle = {},
  journal = {{A}ntiviral {T}herapy},
  volume = {15},
  numero = {1},
  pages = {121--126},
  ISSN = {1359-6535},
  year = {2010},
  DOI = {10.3851/imp1478},
  URL = {https://www.documentation.ird.fr/hor/fdi:010081632},
}